Dr. Maged Khalil, MD
Claim this profileLehigh Valley Health Network
Studies Cancer
Studies Solid Tumors
5 reported clinical trials
26 drugs studied
Area of expertise
1Cancer
MMR positive
MSI positive
Stage III
2Solid Tumors
Stage III
MMR positive
MSI positive
Affiliated Hospitals
Clinical Trials Maged Khalil, MD is currently running
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
PD-1 Blockade + Chemoradiation
for Cancer
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Recruiting1 award Phase 227 criteria
More about Maged Khalil, MD
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Maged Khalil, MD has experience with
- Pembrolizumab
- Nivolumab
- TSR-042
- Enfortumab Vedotin
- Cabazitaxel
- Prednisone
Breakdown of trials Maged Khalil, MD has run
Cancer
Prostate Cancer
Rectal Cancer
Transitional Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maged Khalil, MD specialize in?
Maged Khalil, MD focuses on Cancer and Solid Tumors. In particular, much of their work with Cancer has involved MMR positive patients, or patients who are MSI positive.
Is Maged Khalil, MD currently recruiting for clinical trials?
Yes, Maged Khalil, MD is currently recruiting for 3 clinical trials in Allentown Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Maged Khalil, MD has studied deeply?
Yes, Maged Khalil, MD has studied treatments such as Pembrolizumab, Nivolumab, TSR-042.
What is the best way to schedule an appointment with Maged Khalil, MD?
Apply for one of the trials that Maged Khalil, MD is conducting.
What is the office address of Maged Khalil, MD?
The office of Maged Khalil, MD is located at: Lehigh Valley Health Network, Allentown, Pennsylvania 18103 United States. This is the address for their practice at the Lehigh Valley Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.